DS
SRRA

David Shaw’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

David Shaw’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-435
Closed -$30K – 3958
2019
Q1 		$30K Sell
435
-40
-8% -$2.57K ﹤0.01% 3532
2018
Q4 		$25K Sell
475
-98
-17% -$6.26K ﹤0.01% 3703
2018
Q3 		$39K Buy
+573
New +$52K ﹤0.01% 3665
2017
Q4 		– Sell
-1,058
Closed -$66K – 3800
2017
Q3 		$66K Sell
1,058
-215
-17% -$12.6K ﹤0.01% 3391
2017
Q2 		$60K Sell
1,273
-857
-40% -$43.7K ﹤0.01% 3298
2017
Q1 		$130K Sell
2,130
-118
-5% -$6.86K ﹤0.01% 3176
2016
Q4 		$134K Buy
2,248
+1,406
+167% +$87.7K ﹤0.01% 3328
2016
Q3 		$61K Buy
+842
New +$65.1K ﹤0.01% 3315

Other funds holding SRRA

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

David Shaw's SRRA Position: Q2 2019 in Review

David Shaw sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q2 2019, closing a stake of 435 shares — an estimated $30K sold.

David Shaw first reported a position in SRRA in Q3 2016 and held it in 8 quarters. The position peaked at $134K in Q4 2016. 49 funds tracked by Wall St. Rank hold SRRA as of Q2 2019.

  • David Shaw reported no remaining Sierra Oncology, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • David Shaw sold 435 Sierra Oncology, Inc. Common Stock shares in Q2 2019, an estimated $30K.
  • David Shaw first reported a position in Sierra Oncology, Inc. Common Stock in Q3 2016 and held it in 8 quarters.
  • David Shaw's Sierra Oncology, Inc. Common Stock position peaked at $134K in Q4 2016.
  • 49 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q2 2019.

Based on D.E. Shaw & Co's 13F filing for Q2 2019, filed 14 Aug 2019.